Mouse anti-COVID-19/SARS-CoV-2 Monoclonal Antibody (Neutralizing)_KMD Bioscience

>>

>>

>>

Primary Antibodies

>

Mouse anti-COVID-19/SARS-CoV-2 Monoclonal Antibody (Neutralizing)

Mouse anti-COVID-19/SARS-CoV-2 Monoclonal Antibody (Neutralizing)

Product Number

MAV109

Alias

Native SARS-CoV-2 Neutralizing antibody, 2019-nCoV

Specifications

100ul
500ul

DATASHEET MSDS

Inquire Now Add to Inquiry List Bulk Packaging Customization

Product Description

Alias	Native SARS-CoV-2 Neutralizing antibody, 2019-nCoV
Catalog Number	MAV109
Product Description	The product is specific for native SARS-CoV-2 antigen.
Molecular Name	COVID-19
Species	COVID-19
Host	Mouse
Size	100ul, 500ul
Clonity	Monoclonal
Clone Number	3F6
Concentration	1mg/ml
Antibody Isotype	IgG1
Formulation	0.01M PBS, pH 7.4
Background	The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond.
Immunogen	Inactivated Native Virus
Application	ELISA, Neu
Biological Activity	N.A
Cross-reactivity	Reaction and neutrolization with native SARS-CoV-2 virus.
Storage Condition	This product can be stored at 2℃-8℃ for one month. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.
Product Declaration	This product is for research use only and must not be used directly on humans or for injection.

Recommended Products

400-621-6806
3599163699
Monday to Friday 9:00-18:00
0